4.6 Article

Diabetes is a risk factor for knee osteoarthritis progression

Journal

OSTEOARTHRITIS AND CARTILAGE
Volume 23, Issue 6, Pages 851-859

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.joca.2015.01.013

Keywords

Knee osteoarthritis; Radiological progression; Metabolic syndrome; Diabetes; Obesity

Funding

  1. Servier
  2. Merck Sharp and Dohme
  3. Lilly
  4. Rottapharm
  5. IBSA
  6. Genevrier
  7. Novartis
  8. Roche
  9. GlaxoSmithKline
  10. Teijin
  11. Teva
  12. Ebewee Pharma
  13. Zodiac
  14. Analis
  15. Theramex
  16. Nycomed
  17. Novo-Nordisk
  18. Nolver
  19. Negma
  20. Wyeth
  21. Amgen
  22. Merckle
  23. NPS
  24. UCB
  25. Bristol Myers Squibb
  26. Merck Sharp Dohme
  27. Nutraveris
  28. Pfizer
  29. SMB
  30. Bayer
  31. Sanofi
  32. Genzyme
  33. Expanscience
  34. Abbot
  35. BioIberica
  36. Fidia
  37. GSK
  38. Alliance for Better Bone Health
  39. MSD
  40. Eli Lilly
  41. Merck
  42. Medtronic
  43. Flexion therapics
  44. Moebius
  45. Pierre Fabre
  46. Nordic Pharma
  47. MRC [MC_U147585819, G0400491, MC_U147585827] Funding Source: UKRI
  48. Medical Research Council [U1475000001, MC_UP_A620_1014, MC_UU_12011/1, MC_U147585819, MC_U147585827, MC_U147585824, G0400491] Funding Source: researchfish
  49. National Institute for Health Research [NF-SI-0513-10085, CL-2006-18-006, CL-2014-26-001, NF-SI-0508-10082] Funding Source: researchfish

Ask authors/readers for more resources

Purpose: Recent studies have suggested that metabolic factors (obesity, diabetes, hypertension and dyslipidemia) and their clustering in metabolic syndrome (MetS) might be involved in the pathophysiology of knee osteoarthritis (OA). We investigated their impact on radiographic progression by an annualised measure of the joint space narrowing (JSN) of the medial tibiofemoral compartment. Methods: 559 patients older than 50 years with symptomatic knee OA were recruited for the placebo arm of the SEKOIA trial. The presence of diabetes, hypertension and dyslipidemia was determined at baseline interview. Body mass index (BMI) was calculated, obesity was considered >30 kg/m(2). MetS was defined by the sum of metabolic factors >= 3. Minimal medial tibiofemoral joint space on plain radiographs was measured by an automated method at baseline and then annually for up to 3 years. Results: The mean age of patients was 62.8 [62.2-63.4] years; 392 were women. A total of 43.8% was obese, 6.6% had type 2 diabetes, 45.1% hypertension, 27.6% dyslipidemia and 13.6% MetS. Mean annualised JSN was greater for patients with type 2 diabetes than without diabetes (0.26 [-0.35 to -0.17] vs 0.14 [-0.16 to -0.12] mm; P = 0.001). This association remained significant after adjustment for sex, age, BMI, hypertension and dyslipidemia (P = 0.018). In subgroup analysis, type 2 diabetes was a significant predictor of JSN in males but not females. The other metabolic factors and MetS were not associated with annualised JSN. Conclusion: Type 2 diabetes was a predictor of joint space reduction in men with established knee OA. No relationships were found between MetS or other metabolic factors and radiographic progression. (C) 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available